MedTrace Logo

Positron Emission Tomography (PET) Study

NCT00886067 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2009-09-10

No results posted yet for this study

Summary

The primary purpose is to study the occupancy at the α4β2 neuronal nicotinic receptor's (NNRs) and to determine the relation between plasma concentration of AZD1446 and the occupancy at α4β2 NNRs.

Conditions

  • Healthy

Interventions

DRUG

AZD1446

Solution, oral, single dose

RADIATION

2-[18F]-F-A85380

iv, single dose

Sponsors & Collaborators

Principal Investigators

  • Björn Paulsson, MD, PhD · AstraZeneca Södertälje

  • Ingemar, Bylesjö, MD, PhD · AstraZeneca CPU Huddinge

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2009-08-31
Completion
2009-08-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00886067 on ClinicalTrials.gov